Response by Jones et al to Letter Regarding Article, “Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
We appreciate the opportunity to respond to a letter written by Moris et al regarding our article, “Ticagrelor Compared With Clopidogrel in Patients With Prior Revascularization for Peripheral Artery Disease,” published in Circulation in November 2016.1 To the authors’ first point, we agree that the subgroup of patients in EUCLID (Examining Use of Ticagrelor in PAD) who did not undergo prior revascularization (named “Enrolled Based on ABI Criteria”) is of interest, and we plan to pursue additional publications in the near future. Second, we reported the timing of prior revascularization, rates of most recent endovascular and surgical revascularization, location of most recent endovascular revascularization, and type of surgical revascularization (Table 1), but we did not perform statistical modeling of specific patient …